LONDON, June 21, 2013 /PRNewswire/ --
On Thursday, June 20, 2013, shares in medical device companies ended mostly lower, tracking losses in the broader market which tumbled for a second successive day following comments from Federal Reserve Chairman Ben Bernanke on the central bank's $85 billion a month bond buying program. The major movers in the Medical Appliances & Equipment industry included Hologic Inc. (NASDAQ: HOLX), St. Jude Medical Inc. (NYSE: STJ), Edwards Lifesciences Corp. (NYSE: EW), Navidea Biopharmaceuticals Inc. (NYSEMKT: NAVB), and ResMed Inc. (NYSE: RMD). All these companies are tracked by AAAResearchReports.com. Free technical research reports on HOLX, STJ, EW, NAVB, and RMD can be accessed by signing up at
Shares in Hologic Inc. ended sharply lower on Thursday, extending their losses from previous trading sessions. The company's shares closed yesterday's session at $19.68, down 3.67%, following a trading range between $19.61 and $20.33. Further, a total of 3.41 million shares were traded, which is above the daily average volume of 2.79 million. Hologic's shares have declined by over 8.10% in the last three trading sessions. Download free report on HOLX upon registration at:
St. Jude Medical Inc.'s shares traded between $43.97 and $45.02 before finishing the day 2.76% lower at $44.07. The shares saw a trading volume of 2.55 million which is above their daily average volume of 2.26 million. St. Jude Medical's shares have dropped by 3.48% in the last three trading sessions. However, despite the recent losses, the stock is still trading near its 52-week high of $47.45. STJ technical report can be accessed for free by signing up at:
Shares in Edwards Lifesciences Corp. fell sharply on Thursday, tracking losses in the broader market. The company's shares closed the session 3.10% lower at $66.69. The share price oscillated between $66.60 and $68.49 throughout the day. A total of 798,249 shares were traded, which is below the daily average volume of 1.48 million. Edwards Lifesciences' shares have declined by 5.38% in the last three trading sessions. Further, the stock is currently trading near its 52-week low of $62.34. A free report on EW can be accessed by registering at:
Navidea Biopharmaceuticals Inc. closed Thursday's session on a lower note, extending its losses from previous trading days. The company's shares ended the day 2.73% lower at $2.49 after trading between $2.46 and $2.57. The company's shares registered a trading volume of 460,609 during the session, below their daily average volume of 625,792. Further, the company's shares have fallen by over 7.40% in the last three trading sessions. Register with AAA Research Reports and download research on NAVB for free at:
Shares in ResMed Inc. ended slightly lower on Thursday, finishing at $47.24, down 0.21% from its previous closing price. The company's shares traded between $45.32 and $47.78; and registered a trading volume of 1.58 million, above their daily average of 944,748. Further, ResMed's shares have declined by 1.30% in the last three trading sessions. Read full free research on RMD by signing up to AAA Research Reports at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE AAA Research Reports